Literature DB >> 29414699

Propagation of an Aβ Dodecamer Strain Involves a Three-Step Mechanism and a Key Intermediate.

Dexter N Dean1, Pratip Rana2, Ryan P Campbell1, Preetam Ghosh2, Vijayaraghavan Rangachari3.   

Abstract

Proteinaceous deposits composed of fibrillar amyloid-β (Aβ) are the primary neuropathological hallmarks in Alzheimer disease (AD) brains. The nucleation-dependent aggregation of Aβ is a stochastic process with frequently observed heterogeneity in aggregate size, structure, and conformation that manifests in fibril polymorphism. Emerging evidence indicates that polymorphic variations in Aβ fibrils contribute to phenotypic diversity and the rate of disease progression in AD. We recently demonstrated that a dodecamer strain derived from synthetic Aβ42 propagates to morphologically distinct fibrils and selectively induces cerebral amyloid angiopathy phenotype in transgenic mice. This report supports the growing contention that stable oligomer strains can influence phenotypic outcomes by faithful propagation of their structures. Although we determined the mechanism of dodecamer propagation on a mesoscopic scale, the molecular details of the microscopic reactions remained unknown. Here, we have dissected and evaluated individually the kinetics of macroscopic phases in aggregation to gain insight into the process of strain propagation. The bulk rates determined experimentally in each phase were used to build an ensemble kinetic simulation model, which confirmed our observation that dodecamer seeds initially grow by monomer addition toward the formation of a key intermediate. This is followed by conversion of the intermediate to fibrils by oligomer elongation and association mechanisms. Overall, this report reveals important insights into the molecular details of oligomer strain propagation involved in AD pathology.
Copyright © 2017 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29414699      PMCID: PMC5985009          DOI: 10.1016/j.bpj.2017.11.3778

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  39 in total

1.  Amyloid β-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process.

Authors:  Erik Hellstrand; Barry Boland; Dominic M Walsh; Sara Linse
Journal:  ACS Chem Neurosci       Date:  2009-10-09       Impact factor: 4.418

Review 2.  Kinetics and thermodynamics of amyloid fibril assembly.

Authors:  Ronald Wetzel
Journal:  Acc Chem Res       Date:  2006-09       Impact factor: 22.384

3.  Dynamics of polymerization shed light on the mechanisms that lead to multiple amyloid structures of the prion protein.

Authors:  Maria-Teresa Alvarez-Martinez; Pascaline Fontes; Viviana Zomosa-Signoret; Jacques-Damien Arnaud; Erwan Hingant; Laurent Pujo-Menjouet; Jean-Pierre Liautard
Journal:  Biochim Biophys Acta       Date:  2011-06-16

4.  Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's disease.

Authors:  Johnny Habchi; Sean Chia; Ryan Limbocker; Benedetta Mannini; Minkoo Ahn; Michele Perni; Oskar Hansson; Paolo Arosio; Janet R Kumita; Pavan Kumar Challa; Samuel I A Cohen; Sara Linse; Christopher M Dobson; Tuomas P J Knowles; Michele Vendruscolo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-23       Impact factor: 11.205

5.  Specific soluble oligomers of amyloid-β peptide undergo replication and form non-fibrillar aggregates in interfacial environments.

Authors:  Amit Kumar; Lea C Paslay; Daniel Lyons; Sarah E Morgan; John J Correia; Vijayaraghavan Rangachari
Journal:  J Biol Chem       Date:  2012-04-27       Impact factor: 5.157

6.  Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.

Authors:  Wesley Jongbloed; Kim A Bruggink; Maartje I Kester; Pieter-Jelle Visser; Philip Scheltens; Marinus A Blankenstein; Marcel M Verbeek; Charlotte E Teunissen; Robert Veerhuis
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

7.  Critical nucleus size for disease-related polyglutamine aggregation is repeat-length dependent.

Authors:  Karunakar Kar; Murali Jayaraman; Bankanidhi Sahoo; Ravindra Kodali; Ronald Wetzel
Journal:  Nat Struct Mol Biol       Date:  2011-02-13       Impact factor: 15.369

8.  Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue.

Authors:  Jun-Xia Lu; Wei Qiang; Wai-Ming Yau; Charles D Schwieters; Stephen C Meredith; Robert Tycko
Journal:  Cell       Date:  2013-09-12       Impact factor: 41.582

9.  Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation.

Authors:  Alexander K Buell; Céline Galvagnion; Ricardo Gaspar; Emma Sparr; Michele Vendruscolo; Tuomas P J Knowles; Sara Linse; Christopher M Dobson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-09       Impact factor: 11.205

10.  Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism.

Authors:  Samuel I A Cohen; Sara Linse; Leila M Luheshi; Erik Hellstrand; Duncan A White; Luke Rajah; Daniel E Otzen; Michele Vendruscolo; Christopher M Dobson; Tuomas P J Knowles
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-23       Impact factor: 11.205

View more
  3 in total

1.  Charge and redox states modulate granulin-TDP-43 coacervation toward phase separation or aggregation.

Authors:  Anukool A Bhopatkar; Shailendra Dhakal; Hannah G Abernathy; Sarah E Morgan; Vijayaraghavan Rangachari
Journal:  Biophys J       Date:  2022-04-30       Impact factor: 3.699

2.  A game-theoretic approach to deciphering the dynamics of amyloid-β aggregation along competing pathways.

Authors:  Preetam Ghosh; Pratip Rana; Vijayaraghavan Rangachari; Jhinuk Saha; Edward Steen; Ashwin Vaidya
Journal:  R Soc Open Sci       Date:  2020-04-29       Impact factor: 2.963

3.  Biophysical characteristics of lipid-induced Aβ oligomers correlate to distinctive phenotypes in transgenic mice.

Authors:  Jhinuk Saha; Dexter N Dean; Shailendra Dhakal; Kelli A Stockmal; Sarah E Morgan; Kristy D Dillon; Munir F Adamo; Yona Levites; Vijayaraghavan Rangachari
Journal:  FASEB J       Date:  2021-02       Impact factor: 5.834

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.